By conducting thorough assessments of our clients’ requirements, we provide tailored and effective solutions to meet the industry’s demanding regulatory standards. Customized delivery systems, manufacturing methods and an aggressive approach to regulatory compliance enable us to provide reliable solutions at every step of the process.
Our team has extensive GMP experience in developing viral vaccines. We can produce GMP batches of adenoviral, adeno-associated virus (AAV) and Modified Vaccinia Ankara (MVA) vectors in both adherent and suspension cell lines. ReiThera can support large-scale production up to 100 Liters.
Our team has expertise in downstream processing for a wide range of products. We can accommodate our clients’ product purification needs at different scales. The ReiThera team has produced and released over 30 GMP batches of products for use in multiple clinical trials worldwide, including two Phase II studies. We have experience in designing and documenting processes that ensure a successful product development experience.
We offer the following services for adenoviral, AAV, MVA and replication-competent adenovirus:
- GMP virus banking and characterization
- GMP cell banking and characterization
- Adherent and suspension cells
- Large-scale ultra/diafiltration
- Depth filtration
- Chromatographic purification
- Aseptic fill/finish
Contact us for more information, to discuss your project or to request a quote.